Treatment of FGF-mediated conditions by administration of a card

Details Treatment of FGF-mediated conditions by administration of a card Treatment of FGF-mediated conditions by administration of a card

1998-12-14

2000-06-06

Fonda, Kathleen K.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514 25, 514 27, 514 28, 514 29, 514 30, 514 31, 435184, 530351, 530396, 530399, A61K 31705, A01N 4500, C07K 100

Patent

active

060718854

ABSTRACT:
This invention provides methods of inhibiting the export of a leaderless protein from a cell by contacting the cell with a cardiac glycoside or aglycone derivative. Leaderless proteins include FGF-1, FGF-2, IL-1.alpha., IL-1.beta. and factor XIIIa. These methods are useful in treatment of conditions, including tumors and diabetes.

REFERENCES:
patent: 5545623 (1996-08-01), Matsumori
patent: 5627195 (1997-05-01), Hu
patent: 5872103 (1999-02-01), Belletti
Katahira et al. Chemotherapy Jul. 1991, 39(7), 678-686.
Callard et al. "The Cytokine FactsBook" Academic Press Limited, London, 1994, pp. 31-38.

Affiliated with

Also associated with

Rating

Treatment of FGF-mediated conditions by administration of a card does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of FGF-mediated conditions by administration of a card, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of FGF-mediated conditions by administration of a card will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2213653